HUP0302622A2 - Ellenőrzött hatóanyag-leadású, biológiailag lebontható mikrorészecskék, amelyek csökkentett molekulatömegű, tisztított amilopektinalapú keményítőt tartalmaznak - Google Patents

Ellenőrzött hatóanyag-leadású, biológiailag lebontható mikrorészecskék, amelyek csökkentett molekulatömegű, tisztított amilopektinalapú keményítőt tartalmaznak

Info

Publication number
HUP0302622A2
HUP0302622A2 HU0302622A HUP0302622A HUP0302622A2 HU P0302622 A2 HUP0302622 A2 HU P0302622A2 HU 0302622 A HU0302622 A HU 0302622A HU P0302622 A HUP0302622 A HU P0302622A HU P0302622 A2 HUP0302622 A2 HU P0302622A2
Authority
HU
Hungary
Prior art keywords
starch
molecular weight
reduced molecular
controlled release
microparticles
Prior art date
Application number
HU0302622A
Other languages
English (en)
Inventor
Nils Ove Gustavsson
Monica Jönsson
Timo Laakso
Mats Reslow
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003615A external-priority patent/SE517421C2/sv
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of HUP0302622A2 publication Critical patent/HUP0302622A2/hu
Publication of HUP0302622A3 publication Critical patent/HUP0302622A3/hu

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/20—After-treatment of capsule walls, e.g. hardening
    • B01J13/22—Coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Eljárás parenterálisan beadható mikrorészecskék előállítására, olymódon, hogy csökkentett molekulatömegű, tisztított amilopektin-alapúkeményítőből legalább 20 tömeg%-os vizes oldatot készítenek, azoldatot biológiailag aktív anyaggal elegyítik, keményítőcseppekemulziója képződik egy külső fázist alkotó polimeroldatban, akeményítőcseppeket gélesítik és a gélesedett keményítő részecskéketmegszárítják. A részecskékre adott esetben hatóanyag-leadást szabályzóhéjat visznek föl. A találmány a mikrorészecskékre is vonatkozik,melyek lényegében a kérdéses keményítőből állnak, aminosav tartalmukkevesebb, mint 50 mg és híjával vannak a kovalens kémiaikeresztkötéseknek. Ó
HU0302622A 2000-10-06 2001-10-05 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight HUP0302622A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0003615A SE517421C2 (sv) 2000-10-06 2000-10-06 Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
US26045501P 2001-01-08 2001-01-08
PCT/SE2001/002164 WO2002028370A1 (en) 2000-10-06 2001-10-05 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight

Publications (2)

Publication Number Publication Date
HUP0302622A2 true HUP0302622A2 (hu) 2003-11-28
HUP0302622A3 HUP0302622A3 (en) 2006-07-28

Family

ID=26655255

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302622A HUP0302622A3 (en) 2000-10-06 2001-10-05 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight

Country Status (10)

Country Link
US (1) US20020098203A1 (hu)
EP (2) EP1322290A1 (hu)
JP (2) JP2004510723A (hu)
KR (1) KR20030051687A (hu)
CN (1) CN100352427C (hu)
AU (3) AU2001294458B2 (hu)
CA (2) CA2424892A1 (hu)
HK (1) HK1061981A1 (hu)
HU (1) HUP0302622A3 (hu)
WO (2) WO2002028371A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US20070218139A1 (en) 2002-12-20 2007-09-20 Smith Thomas J High Pressure Compaction For Pharmaceutical Formulations
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
CA2566075A1 (en) * 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
US20060269576A1 (en) * 2005-05-27 2006-11-30 Curalogic, A/S Non-injection immunotherapy
US8017152B2 (en) 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
EP1726299A3 (en) 2005-05-27 2007-04-18 StratoSphere Pharma AB Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
WO2007025441A1 (en) * 2005-08-29 2007-03-08 Tuo Jin Polysaccharide microparticles containing biological agents: there preparation and applications
ES2462519T3 (es) * 2005-10-25 2014-05-23 Artificial Cell Technologies, Inc. Composiciones inmunógenas y procedimientos de uso
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
KR100956415B1 (ko) * 2008-06-13 2010-05-06 이진호 고분자 구형입자의 제조방법
CN102209530B (zh) * 2008-10-10 2013-05-15 普罗贝尔特医药公司 用于水产养殖的可口服给药的免疫刺激产品
JP5361407B2 (ja) * 2009-01-21 2013-12-04 株式会社東芝 Ｘ線画像診断装置、画像処理装置及び制御プログラム
WO2012054807A2 (en) * 2010-10-22 2012-04-26 President And Fellows Of Harvard College Vaccines comprising bisphosphonate and methods of use thereof
BR112013014574B1 (pt) * 2010-12-15 2019-10-15 Speximo Ab Emulsão ou espuma estabilizada por partícula, uso de uma emulsão estabilizada por partícula e formulação
BR112014026957A8 (pt) * 2012-05-03 2018-01-16 Janssen R&D Ireland micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
US11470811B2 (en) * 2012-09-11 2022-10-18 Pioneer Pet Products, Llc Extruded granular absorbent
SG11201507751YA (en) 2013-03-21 2015-10-29 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
EP3310383B1 (en) * 2015-06-19 2020-02-19 Sillajen, Inc. Compositions and methods for viral embolization
AU2016343952A1 (en) 2015-10-27 2018-05-10 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
CN106902716B (zh) * 2017-02-27 2020-02-14 广西科学院 一种小粒径淀粉微球的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
JPH0699529B2 (ja) * 1985-06-28 1994-12-07 モンサント化成株式会社 シアン化ビニル化合物／芳香族ビニル化合物共重合樹脂の製造方法
AU4109493A (en) * 1992-04-20 1993-11-18 Bruce K. Redding Jr. Method and apparatus for the modification of starch and other polymers
DE69505949T2 (de) * 1994-02-17 1999-06-02 Pankaj Hamilton Ontario Modi Arzneimittel, impfstoffe und hormone in polylaktidbeschichteten mikropartikel
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5959102A (en) * 1997-06-30 1999-09-28 Rutgers University Starch purification by thermally tolerant broad pH range proteolytic enzymes
NL1006444C2 (nl) * 1997-07-01 1999-01-05 Inst Voor Agrotech Onderzoek Inkapseling van werkzame stoffen.
SE512663C2 (sv) * 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer

Also Published As

Publication number Publication date
CN1468093A (zh) 2004-01-14
HUP0302622A3 (en) 2006-07-28
WO2002028370A1 (en) 2002-04-11
HK1061981A1 (en) 2004-10-15
CA2424936A1 (en) 2002-04-11
KR20030051687A (ko) 2003-06-25
CN100352427C (zh) 2007-12-05
US20020098203A1 (en) 2002-07-25
AU9445801A (en) 2002-04-15
CA2424892A1 (en) 2002-04-11
JP2004510724A (ja) 2004-04-08
EP1322291A1 (en) 2003-07-02
AU2001292529A1 (en) 2002-04-15
EP1322290A1 (en) 2003-07-02
JP2004510723A (ja) 2004-04-08
WO2002028371A1 (en) 2002-04-11
AU2001294458B2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
HUP0302622A2 (hu) Ellenőrzött hatóanyag-leadású, biológiailag lebontható mikrorészecskék, amelyek csökkentett molekulatömegű, tisztított amilopektinalapú keményítőt tartalmaznak
SE0003615L (sv) Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
KR910015288A (ko) 서방성 마이크로캡슐
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
BR0013720A (pt) Formulação em pelota de liberação controlada
CY1117889T1 (el) Πολυμερες γαλακτικου οξεος και διεργασια για την παραγωγη αυτου
BR9814729A (pt) Método e composição de uma preparação oral de itraconazol
PL358103A1 (en) Hydrophilic molecular disperse solutions of carvedilol
WO1998009597A3 (en) Cushioning beads and tablet comprising the same capable of forming a suspension
BR0008059A (pt) Composições de valdecoxib
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
DE69837945D1 (de) Tablette, umfassend ein phosphatbindendes Polymer
KR940021071A (ko) 생체기능조정물질
PT85105B (pt) Processo para a preparacao de composicoes farmaceuticas com libertacao controlada da substancia activa
HUP0000141A2 (hu) Eljárás legfeljebb 90 tömeg% gyógyhatású anyagot tartalmazó pelletek előállítására
MY139606A (en) Sustained-release composition and process for producing the same
Wu et al. Time lasting S-nitrosoglutathione polymeric nanoparticles delay cellular protein S-nitrosation
ATE149826T1 (de) Verfahren zur herstellung von festen pharmazeutischen retardformen
EP1061904A1 (de) Nanopartikel, verfahren zu ihrer herstellung und ihre verwendung
BR0114512A (pt) Suspensão coloidal, sólido pulverulento, processos de preparação, produtos intermediários de processo, especialidade farmacêutica, nutricional, fitossanitária ou cosmética e uso de uma suspensão coloidal estável
CA2326048A1 (en) Peroral active agent suspension
BRPI0614080A2 (pt) Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose
JO2325B1 (en) A pharmaceutical composition with a flavoring taste and a process to prepare it
Ma et al. PCL/poloxamer 188 blend microsphere for paclitaxel delivery: Influence of poloxamer 188 on morphology and drug release
TR200703565T1 (tr) Peroral uygulanabilir antimikrobiyal kompozisyon.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees